A HUVEC line with a stable expression of the VEGF121 gene to achieve complete endothelialization of blood conduits

Artificial Cells, Blood Substitutes, and Biotechnology

Volumn 35, Issue 3, 2007, Pages 319-331

  Liu, L S ^a   Wei, D H ^a   Tang, C K ^a   Wang, G X ^b   Zhang, S C ^b   Yin, W D ^b   Yang, Y Z ^b   Legrand, A P ^c   Guidoin, R ^d  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b CHONGQING UNIVERSITY   (China)

^c PSL RESEARCH UNIVERSITY   (France)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

Lipofect AMINE; Stable transfection; Vascular tissue engineering; VEGF

Indexed keywords

AMINES; BIOACTIVITY; CELLS; IMMUNOLOGY; PROTEINS; TISSUE ENGINEERING; TRANSCRIPTION;

BLOOD CONDUITS; ENDOTHELIALIZATION; LIPOFECT AMINE; STABLE TRANSFECTION; VEGF;

GENES;

LIPOFECTAMINE; MESSENGER RNA; VASCULOTROPIN 121;

ARTICLE; BIOLOGICAL ACTIVITY; BLOOD VESSEL GRAFT; CELL ADHESION; CELL CLONE; CELL GROWTH; CONTROLLED STUDY; ENDOTHELIUM CELL; EUKARYOTE; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELL LINE; IMMUNOCYTOCHEMISTRY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING; STENT; TISSUE ENGINEERING; TRANSCRIPTION REGULATION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

BASE SEQUENCE; CELL ADHESION; CELL DIVISION; CELL LINE; COATED MATERIALS, BIOCOMPATIBLE; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; HUMANS; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STENTS; TISSUE ENGINEERING; TRANSFECTION; UMBILICAL ARTERIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EUKARYOTA;

EID: 34250719307     PISSN: 10731199     EISSN: 15324184     Source Type: Journal    
DOI: 10.1080/10731190701378642     Document Type: Article

References (39)

1. Dotter, C.T. (1969). Transluminally-placed coil spring endarterial tube grafts. Long-term potency in canine propliteal artery. Invest. Radiol. 4: 326-332.
2. Dotter, C.T., Judkins, M.P. (1989). Transluminal treatment of arteriosclerotic obstruction. Description of a new technic and a preliminary report of its application. Radiology 172: 904-920.
3. Dotter, C.T., Buschmann, R.W., McKinney, M.K., Rosch, J. (1983). Tranluminal expandable Nitinol coil stent grafting: preliminary report. Radiology 146: 259-260.
4. Palmaz, J.C. (2004). Intravascular stents in the last and the next 10 years. J. Endovasc. Ther. 7(Suppl. 2): II200-II206.
5. Parodi, J.C., Criado, F.J., Barone, M.D., Schonholz, C., Queral, L.A. (1994). Endoluminal aortic aneurysm repair using a balloon-expandable stent-graft device: a progress report. Ann. Vasc. Surg. 8: 523-529.
6. Parodi, J.C. (1996). Endovascular repair of aortic aneurysm, arteriovenous fistulas, and false aneurysm. World J. Surg. 20: 655-663.
7. Parodi, J.C. (1997). Endolumineal treatment of arterial disease using stent-graft combination: reflections 20 years after the initial concept. J. Endovasc. Surg. 4: 3-4.
8. Berger, K., Sauvage, L.R., Rao, A.M., Wood, S.J. (1982). Healing of arterial prostheses in man: Its incompleteness. Ann. Surg. 165: 118-127.
9. Shi, Q., Wa, M.H., Onuki, Y., Hunter, G.C., Johansen, K.H., Sauvage, L.R. (1997). Endothelium on the flow surface of human aortic Dacron vascular grafts. J. Vasc. Surg. 25: 736-742.
10. Guidoin, R., Guzman, R., Charrara, J., Gosselin, C. (1991). Fate of arterial prostheses: Healing characteristics and delayed complications, in Biomaterials Degradation. Fundamental Aspects and Related Clinical Phenomena, M.A. Barbosa, Ed., Elsevier Science Publisher BV: Amsterdam, pp. 53-110.
11. Guidoin, R.,Marois, Y.,Douville,Y.,King,M.W.,Castonguay,M., Traore,A., Formichi, M., Stuxrud, L.E., Norgren, L., Bergeron, P., Becquemin, J.P., Egana, J.M., Harris, P.L. (2000). First generation aortic endografts: Analysis of explanted Stentor devices from the Eurostar registry. J. Endovasc. Ther. 7: 105-122.
12. Palmaz, J.C., Bailey, S., Marton, D., Sprague, E. (2002). Influence of stent design and material composition on procedure outcome. J. Vasc. Surg. 36: 1031-1039.
13. Gunther, R.W.,Vorwerk,D., Bohndorf,K., Klose, K.C.,Kistler,D.,Mann,H., Sieberth, H.G., el-Din, A. (1989). Venous stenoses in dialysis shunts: Treatment with self-expanding metallic stents. Radiology 170: 401-405.
14. Neglen, P., Raju, S. (2004). In-stent recurrent stenosis in stents placed in the lower extremity venous outflow tract. J. Vasc. Surg. 39: 181-187.
15. Wardeh, A.J., Albiero, R., Kay, I.P., Knook, A.H., Wijns, W., Kosuma, K., Nishida, T., Ferrero, V., Levendag, P.C., van Der Giessen, W.J., Colombo, A., Serruys, P.W. (2002). Angiographical follow-up after radioactive "Cold Ends" stent implantation: A multicenter trial. Circulation 105: 550-553.
16. Kalusa, G.L., Gershlick, A.H., Park, S.J., De Scheerder, I., Chevalier, B., Camenzind, E., Goy, J.J., Missault, L., Reifart, N., Vrints, C., Urban, P., Shin, W.H., Ho, D.S., Fearnot, N.E., Voorhees, W.D. 3rd, Raizner, A.E. (2004). Comparison of neointinal formation in polymer-free paxitaxel stents versus stainless stents (from the ASPECT and ELUTES randomized clinical trials). Am. J. Cardiol. 94: 199-201.
17. Machan, L. (2004). Drug eluting stents in the infrainguilinal circulation. Tech. Vasc. Interv. Radiol. 7: 28-32.
18. Sousa, J.E., Serruys, P.W., Costa, M.A. (2003). New frontiers in cardiology: Drug-eluting stents: Part I. Circulation 107: 2274-2279.
19. Sousa, J.E., Serruys, P.W., Costa, M.A. (2003). New frontiers in cardiology: Drug-eluting stents: Part II. Circulation 107: 2383-2389.
20. Baer, R.P., Whitehill, T.E., Sarkar, R., Sarkar, M., Messina, L.M., Komorowski, T.A., Stanley, J.C. (1996). Retroviral-mediated transduction of endothelial cells with the lac Z gene impairs cellular proliferation in-vitro and graft endothelization in-vivo. J. Vasc. Surg. 24: 892-899.
21. Dichek, D.A., Neville, R.F., Zwiebel, A.J., Freeman, S.M., Leon, M.B., Anderson, W.F. (1989). Seeding of intravascular stents with genetically engineered endothelial cells. Circulation 80: 1347-1353.
22. Huber, T.S., Welling, T.H., Sarkar, R., Messina, L.M., Stanley, J.C. (1995). Effects of retroviral-mediated tissue plasminogen activator gene transfer and expression on adherence and proliferation of canine endothelial cells seeded onto expanded polytetrafluorethylene. J. Vasc. Surg. 22: 795-803.
23. Kader, K.N., Akella, R., Ziats, N.P., Lakey, L.A., Harasaki, H., Ranieri, J.P., Bellamkonda, R.V. (2000). eNOS-overexpressing endothelial cells inhibit platelet aggregation and smooth muscle cell proliferation in-vitro. Tissue Eng. 6: 241-251.
24. Sprague, E.A., Luo, J., Palmaz, J.C. (2000). Endothelial cell migration onto metal stent surfaces under static and flow conditions. J. Long Term Eff. Med. Implants 10: 97-110.
25. Asahara, T., Bauters, C., Pastore, C., Kearney, M., Rossow, S., Bunting, S., Ferrara, N., Symes, J.F., Isner, J.M. (1995). Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in ballon-injured rat carotid artery. Circulation 91: 2793-2801.
26. Bauters, C., Asahara, T., Zheng, L.P., Takeshita, S., Bunting, S., Ferrara, N., Symes, J.F., Isner, J.M. (1995). Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemia hindlimb after administration of vascular endothelial growth factor. Circulation 91: 2802-2809.
27. 121 from fibrin implants induces local and controlled blood vessel growth. Circ. Res. 94: 1124-1132.
28. Isner, J.M., Walsh, K., Symes, J., Pieczek, A., Takeshita, S., Lowry, J., Rosssow, S., Rusenfield, K., Weir, L., Brogi, E. et al. (1995). Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation 91: 2687-2692.
29. Morishita, R. (2004). Perspective in progress of cardiovascular gene therapy. J. Pharmacol. Sci. 95: 1-8.
30. 121 on vasculogenesis and angiogenesis in cultured embryogenic quail hearts. Ann. J. Physiol. Heart Circ. Physiol. 280: H2240-H2247.
31. Zisch, A.H., Lutolf, M.P., Ehrbar, M., Raeber, G.P., Rizzi, S.C., Davies, N., Schmokel, H., Bezuidenhout, D., Djonov, V., Zilla, P., Hubbell, J.A. (2003). Cell-demanded release of VEGH from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. FASEB J. 17: 2260-2262.
32. Jaffe, E.A., Hoyer, L.W., Nachman, R.L. (1973). Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J. Clin. Invest. 52: 2757-2764.
33. Miles, A.A., Miles, E.M. (1952). Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea pigs. J. Physiol. 118: 228-257.
34. Fischbeck, J.A., Baier, J.M., Akella, R., Hern-Anderson, D., Schmidt, C.E. (2002). Genetic modification of alphaGal expression in xenogeneic endothelial cells yields a complex immunological response. Tissue Eng. 7: 743-756.
35. Nomi, M., Atala, A., Coppi, P.D., Soker, S. (2002). Principals of neovascularization for tissue engineering. Mol. Aspects Med. 23: 463-483.
36. Nugent, H.M., Edelman, E.R. (2003). Tissue engineering therapy for cardiovascular disease. Circ. Res. 92: 1068-1078.
37. Tiong, A., Freedman, S.B. (2004). Gene therapy for cardiovascular disease: the potential of VEGF. Curr. Opin. Mol. Ther. 6: 151-159.
38. Moses, J.W., Leon, M.B., Popma, J.J., Fitzgerald, P.J., Moles, D.R., O'Shaughnessy, C., Caputo, R.P., Kereiakes, D.J., Williams, D.O., Teirstein, P.S., Jaeger, P.L., Kuntz, R.F. (2003). Sirius investigators. Serolimus-eluting versus standard stents in patients with stenosis in a native coronary artery. New. Engl. J. Med. 349: 1315-1323.
39. Stone, G.W., Ellis, S.G., Cox, D.A., Hermiller, J., O'Shaughnessy, C., Mann, J.T., Turco, C., Caputo, R., Bergin, P., Greenberg, J., Popma, J.J., Russell, M.E. (2004). TAXUS-IV Investigators. A polymer based, paclitaxel-eluting stent in patients with coronary artery disease. New Engl. J. Med. 350: 221-231.